Tango Therapeutics
Tango Therapeutics raises $165M Series B at $600M valuation
Quick Facts
Tango Therapeutics: Series B Funding Round
Tango Therapeutics has successfully raised $165M in Series B funding, reaching a valuation of $600M.
Company Overview
Cancer therapeutics discovering synthetic lethal drug targets
Funding Details
The Series B round was led by Third Rock Ventures, with participation from BVF Partners, Boxer Capital, Casdin Capital.
Company Information
- Headquarters: 100 Binney Street, Cambridge, MA 02142
- Founded: 2017
- Employees: 120+
- Category: Biotech
Investment
Tango Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Series B
- BVF Partners: Verified investor in Series B
- Boxer Capital: Verified investor in Series B
- Casdin Capital: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...